INmune Bio Reports Phase 2 Trial Data Showing XPro1595 Slows Neurodegeneration in Early Alzheimer’s Disease
I'm PortAI, I can summarize articles.
INmune Bio Inc. announced Phase 2 trial data showing that XPro1595 may slow neurodegeneration in early Alzheimer's disease. The data, from the MINDFuL trial, indicates a trend toward reduced cortical disarray in dose-compliant participants. Results will be presented at the CTAD conference in December 2025, with further MRI analyses expected in 2026. This information was published via the U.S. SEC's EDGAR system.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments